Ny lovende behandling afhjælper migræne og klyngehovedpine i op til 12 måneder ad gangen.
Ny kontroversie behandling mod migræne og klyngehovedpine har vist meget lovnde resultater. Selvom behandlingen med Psilocybin stammer fra de halucinerende svampearter Pcilocybe Cubensis mfl., har meget lave ikke halicunerende doser vist lovende resultater. Pga. svampens klasificering som ulovlig, er forskning svær at få godkendt og der er næsten ikke sket noget siden offentliggørelsen af 2006 resultaterne. Hvis du lider af migræne eller klyngehovedpine (Hortons) kan det varmt anbefales at du læser mere nedenfor og mælder dig ind og støtter vores Facebook Gruppe her:
Nedenfor kan du læse mere om forskellige temaer - fra migræne til selvudvikling - Artiklerne er på Engelsk:
——————————————————————————————————————–
Migrene – Cluster headaches psilocybin treatment
Cluster headaches are a rare, severely painful form of headache that is related to but different from the more common migraine. It is the most painful condition known to man. Through experimenting and anecdotal reports, a group of sufferers who now work together under ‘clusterbusters’, found out about the effectiveness of psilocybin and other indole-ring entheogens (LSD,LSA) in cluster headaches. A single small dose(sub hallucinogenic) of mushrooms, has proven to abort attacks, and prevent new cycles.
Migrains and Cluster Headaches have been reported to be haulted for periods up to 6 and 12 months. Please support our efforts by signing up to the Facebook Group about Migraine and Cluster Headache
Kæmp mod migræne -og for mere forskning
Reviews and case studies from patients:
www.youtube.com/watch?v=JASWFASqcps&feature=related
www.erowid.org/plants/mushrooms/mushrooms_medical1.shtml
www.hopkinsmedicine.org/press_releases/2006/07_11_06.html
www.maps.org/research/cluster/psilo-lsd
————————————————————————————————–
Personal Development through “Teacher Plants”
Naturally occurring entheogens such as psilocybin and dimethyltryptamine, also known as N,N-dimethyltryptamine, or simply DMT (From mushrooms or ayahuasca) were, for the most part, discovered and used by older cultures, as part of their spiritual and religious life, as plants and agents which were respected, or in some cases revered for generations and may be a tradition which predates all modern religions.
Entheogens have been used in various ways, including as part of established religions, secularly for personal spiritual development as tools (or “plant teachers”) to augment the mind, see the truth, find one self, for initiation, and for medical and therapeutic use.
The use of entheogens in human cultures is nearly ubiquitous throughout recorded history.
———————————————————————————————————————
Medicinal use of Psilocybin/Psilocin
Research and case reports have shown that psilocybin/psilocin has medicinal and therapeutic potential.
OCD Therapy:
In 2001, Dr. Francisco Moreno at the University of Arizona started the first FDA-approved clinical trial involving a psychedelic in 30 years. In this study, psilocybin was administered to nine obsessive-compulsive disorder patients. The study found that psilocybin could be safely given to patients with OCD, and it was associated with substantial reductions in OCD symptoms in several of the patients.
——————————————————————————————–
Depression, Well-Being and Life-satisfaction:
A new study led by Johns Hopkins researchers has revealed that mystical experiences produced by psilocybin, found in “sacred mushrooms” are likely to persist for longer period.
In the study involving 36 volunteers researchers found that the beneficial effects of Psilocybin were likely to last more than a year.
The subjects given psilocybin increased their sense of well-being or life satisfaction.
“Most of the volunteers looked back on their experience up to 14 months later and rated it as the most, or one of the five most, personally meaningful and spiritually significant of their lives,” said lead investigator Roland Griffiths, Ph.D., a professor in the Johns Hopkins departments of Psychiatry and Behavioral Sciences and Neuroscience.
“While some of our subjects reported strong fear or anxiety for a portion of their day-long psilocybin sessions, none reported any lingering harmful effects, and we didn’t observe any clinical evidence of harm,” he added.
He also said that that study results gives credence to the claims that the mystical-type experiences some people have during hallucinogen sessions may help patients suffering from cancer-related anxiety or depression and may serve as a potential treatment for drug dependence.
In the related paper, researchers also offered recommendations for conducting this type of research.
The guidelines cautioned against giving hallucinogens to people at risk for psychosis or certain other serious mental disorders and detailed guidance is also provided for preparing participants and providing psychological support during and after the hallucinogen experience.
These “best practices” contribute both to safety and to the standardization called for in human research.
“With appropriately screened and prepared individuals, under supportive conditions and with adequate supervision, hallucinogens can be given with a level of safety that compares favourably with many human research and medical procedures,” said that paper’s lead author, Mathew W. Johnson, Ph.D., a psychopharmacologist and instructor in the Johns Hopkins Department of Psychiatry and Behavioral Sciences.
The team also said that if hallucinogens are used in less well-supervised settings, the possible fear or anxiety responses could lead to harmful behaviours.
The study is published in Journal of Psychopharmacology.
www.youtube.com/watch?v=JASWFASqcps&feature=related
——————————————————————————————————————–
